Ultragenyx Pharma (RARE) Tops Q3 EPS by 33c

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.08), $0.33 better than the analyst estimate of ($1.41). Revenue for the quarter came in at $81.6 million versus the consensus estimate of $81.55 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• CVG to join Russell 2000 and Russell 3000 indexes June 26